Low-dose interleukin-2 (Ld-IL2) therapy emerges as a promising new therapy to treat a wide range of inflammatory, autoimmune and alloimmune disorders such as SLE, hepatitis C-induced vasculitis, graft-versus-host disease (GVHD) [1,30]. This evidence concerns the gene IL2 and systemic lupus erythematosus.